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cDNA clones for 17/&hydroxysteroid dehydrogenase (17-HSD; EC 1.1.1.62) were isolated from a placental 6gtll expres- 
sion library using polyclonal antibodies against placental 17-HSD. The largest cDNA contained 1325 nucleotides, consist- 
ing of a short S-noncoding segment, acoding segment of 987 nucleotides terminated by a TAA codon, and a 329 nucleo- 
tide long 3’-noncoding segment. The open reading frame encoded a polypeptide of 327 amino acid residues with a pre- 
dicted M, of 34853. The amino acid sequence of 23 N-terminal amino acids determined from purified 17-HSD agreed 
with the sequence deduced from cDNA. The deduced amino acid sequence also contained two peptides previously charac- 
terized from the proposed catalytic area of placental III-HSD. 
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1. INTRODUCTION 
17&Hydroxysteroid dehydrogenase (17-HSD; 
EC 1.1.1.62) catalyzes interconversion of neutral 
and phenolic 17-hydroxy and 17-ketosteroids. It is 
present in steroid-forming tissues and also in cer- 
tain steroid target tissues such as human en- 
dometrium [ 1,2]. In the latter tissue the activity of 
this enzyme is regulated by progestins [3-51, and it 
possibly has a role in regulating the exposure of the 
endometrium to estrogen action [1,2,4]. A similar 
role for this enzyme in breast tissue has been pro- 
posed [6]. Hence detailed information of the pro- 
perties and regulation of this enzyme may be 
central for our understanding of the hormone 
dependency of endometrial and breast cancer. 
17-HSD has been purified to homogeneity from 
term placental tissue in this [7] and other [8,9] 
laboratories. In its native form, placental 17-HSD 
is composed of two similar if not identical subunits 
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having an M, of about 34000 (see [lo]). 
Preliminary data suggest that human endometrium 
contains a protein showing similar immunological 
properties as the one purified from placental tissue 
171. 
As part of our studies directed towards 
understanding the regulation of 17-HSD in steroid 
target tissues, we report the cloning of the cDNA 
of human placental 17-HSD and provide the com- 
plete amino acid structure of the enzyme deduced 
from the cDNA. 
2. MATERIALS AND METHODS 
2.1. Materials 
A human placental cDNA library in the hgtl 1 expression vec- 
tor was obtained from Clontech (Palo Alto, CA). Restriction 
endonucleases, proteinase K, DNase I, RNase A, and an Ml3 
cloning kit were obtained from Boehringer Mannheim 
(Mannheim, FRG). A SequenaseTM sequencing kit was purchas- 
ed from the United States Biochemical Corporation (Cleveland, 
OH) and [‘%]dATP was from Amersham (Amersham, 
England). Sequence-derived oligonucleotide primers (17 bases) 
were synthesized with a DNA synthesizer (Applied Biosystems, 
Foster City, CA). Nitrocellulose filters were obtained from 
Schleicher and Schuell (Dassel, FRG). 
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Fig.1. The sequencing strategy. The white area represents the 
coding sequence of 17-HSD and the hatched areas the 5’- and 
3 ’ -untranslated regions. M 13 universal primer (*) and sequence 
specific oligonucleotides (01-08) were used to determine the 
complete sequence of both strands. The bar gives the 
approximate scale. 
2.2. I7-HSD antiserum 
Polyclonal antiserum against highly purified placental 
17-HSD was raised in rabbits [7]. Antiserum was absorbed with 
E. co/i strain Yl090r- lysate to remove antibodies that 
recognize E. co/i antigens [ll]. 
2.3. Antibody screening of hgtll library 
About 5 x lo5 plaque-forming units (pfu) of recombinant 
phages from a placental cDNA library were screened with an 
anti-17-HSD-antiserum, diluted 1: 200 in Tris-buffered saline 
containing 20% fetal calf serum [11], with the exception that 
positive plaques were detected by using protein A-peroxidase 
and 4-chloro-1-naphthol as a substrate. Plaques were further 
purified by three to five cycles of screening at low plaque densi- 
ty with antiserum until all phages produced positive signals. 
Eleven positive phage clones were amplified, digested with 
EcoRl, the sizes of the inserts were determined and they were 
purified. 
2.4. cDNA sequence analyses 
The EcoRI inserts from the Xgt 11 clones were subcloned into 
an Ml3mpl8 vector [12]. The DNA sequence was determined 
by the dideoxy chain termination method of Sanger [13] using 
SequenaseTM -enzyme [14] and the universal primer as well as 
synthetic oligonucleotides for priming (fig.1). The two longest 
inserts, one later found to have the whole coding area and the 
other lacking about 40 bases from the 5’-end, were sequenced. 
2.5. Protein sequencing 
Amino acid sequence analysis of 23 N-terminal amino acids 
from purified placental III-HSD was performed with an Ap- 
plied Biosystems model 477A pulse liquid protein/peptide se- 
quencer with a 120A PTH analyzer (Applied Biosystems, Foster 
City, CA). 
3. RESULTS AND DISCUSSION 
A human placental hgtl 1 library was screened 
with antiserum raised against human placental 
17-HSD. As a result of screening 5 x lo5 individual 
plaques, 15 clearly positive plaque clones were 
identified. Eleven plaques remained positive upon 
three to five rounds of rescreening and they were 
amplified and digested with EcoRI. The sizes of 
the inserts varied from 0.8 to 1.3 kb and the two 
longest cDNA inserts (1.2 and 1.3 kb) were se- 
quenced. To compare cDNA-deduced amino acid 
sequence to the sequence of native placental pro- 
tein, 23 amino acids from the N-terminus of the 
purified enzyme were analyzed and the sequences 
were found to be identical. 
The 1.3 kb insert, named h HSD2A, contained 
an open reading frame of 987 bp from the initia- 
tion codon ATG to the stop codon TAA, and addi- 
tionally 9 nucleotides of the 5 ‘- and 329 
nucleotides of the 3’-noncoding segment (fig.2). 
The sequence AATAAA, thought to be required 
for polyadenylation [ 151, was located 16 bp 
upstream from the poly(A) tract. The 1.2 kb in- 
sert, named X HSDSB, contained a sequence from 
nucleotide 40 to nucleotide 1252 of A HSD2A, sug- 
gesting that these two cDNAs were derived from 
the same RNA-pieces. The codon ATG, preceding 
the codon of the first amino acid residue, is ob- 
viously the initiator codon, since the sequence sur- 
rounding it conforms to Kozak’s consensus 
sequence [161. 
Three peptide sequences derived from placental 
17-HSD have been published previously. The se- 
quence of five N-terminal amino acids determined 
by Burns et al. [17] differs in the second amino 
acid; according to our data it is arginine instead of 
glutamate. Nicolas and Harris [ 181 analyzed a 
tryptic heptadecapeptide labeled to a cysteine 
residue. This peptide, suggested to be part of the 
coenzyme binding site in 17-HSD [ 181, is located 
between amino acid residues 51 and 67. The pep- 
tide of 20 amino acid residues sequenced by Mur- 
dock et al. [ 191 is located between residues 204 and 
223 (fig.2). The hydropathicity profile of the 
Fig.2. Nucleotide and deduced amino acid sequence of the subunit of human placental 17-HSD. The numbering of amino acids is based 
on the analysis of the N-terminal sequence of the purified protein (underlined). Two known internal peptides are also underlined (solid 
line). The potential CAMP-dependent kinase phosphorylation site (basic-basic-X-Ser) is indicated with a dot. The putative 
polyadenylation signal site (AATAAA) is marked with a dashed line. 
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ACT CTC ACC ATC CCC CCC ACC CTG CTC CTC ATC ACC CCC TCT TCC TCC CCC ATC CCC CTC 60 
Ala Arg Thr Val Val Leu Ile Thr Gly Cys Ser Ser Cly Ile Cly Leu 16 
CAC TTC CCC GTA CGT CTG GCT TCA CAT CCA TCC CAC AGC TTC AAA CTG TAT CCC ACG TTG 120 
His Leu Ala Val Arg Leu Ala Ser Asp Pro Ser Cln Ser Phe Lys Val Tyr Ala Thr Leu 36 
AGG CAC CTC AAA ACA CAC CCC CCC CTG TGG GAG CCC CCC CGG CCC CTG GCA TGC CCT CCC 180 
Arg Asp Leu Lys Thr Gln Cly Arg Leu Trp Clu Ala Ala Arg Ala Leu Ala Cys Pro Pro 56 
GGA TCC CTG GAG ACG TTG CAC CTG GAC GTA AGG GAC TCA AdA TCC GTG CCC GCT GCC CGG 240 
Gly Ser Leu Glu Thr Leu Gln Leu Asp Val Arg Asp Ser Lys Ser Val Ala Ala Ala Arg 76 
CAR CGC GTG ACT GAG CCC CCC GTG GAC GTG CTG GTG TGT AAC GCA GGC CTG GGC CTG CTG 300 
Glu Arg Val Thr Glu Gly Arg Val Asp Val Leu Val Cys Asn Ala Gly Leu Gly Leu Leu 96 
GGG CCC CTG GAG GCG CTG GGG GAG GAC CCC GTG GCC TCT GTG CTG GAC GTG AAT GTA GTA 360 
Gly Pro Leu Glu Ala Leu Gly Glu Asp Ala Val Ala Ser Val Leu Asp Val Am Val Val 116 
GGG ACT GTG CCC ATG CTG CAG CCC TTC CTG CCA GAC ATG AAG AGG CCC GGT TCG CGA CCC 420 
Gly Thr Val Arg Met Leu Gln Ala Phe Leu Pro Asp Het Lys Arg Arg Gly Ser Gly Arg 136 
GTG TTG GTG ACC CCC AGC GTG CGA CGA TTG ATG GGG CTG CCT TTC AAT GAC GTT TAT TGC 480 
Val Leu Val Thr Gly Ser Val Gly Gly Leu Met Gly Leu Pro Phe Asn Asp Val Tyr Cys 156 
CCC AGC AAG TTC CCC CTC CAA CC% TTA TGC GAG ACT CTG CCC GTT CTG CTG CTC CCC TTT 540 
Ala Ser Lys Phe Ala Leu G:u Gly Leu Cys Glu Ser Leu Afa Val Leu Leu Leu Pro Phe 176 
CCC GTC CAC TTG AK CTG ATC GAG TGC GGC CCA GTG CAC ACC GCC TTC ATG GAG AAG GTG 600 
Gly 'J.al His Leu Ser Leu !le Glu Cys Gly Pro Val His Thr Ala Phe Met Ciu Lys Val 196 
TTG GGC AGC CCA GAG GAG CTG CTG GAC CCC ACG CAC ATC CAC ACC TTC CAC CCC TTC TAC 660 
Leu Gly Ser Pro Clu Glu Val Leu Asp Arg Thr Asp Ile His Thr Phe His Arg Phe Tyr 216 
CAA TAC CTC GCC CAC AGC AAG CAA GTC TTT CCC GAG CCC CCC CAG AAC CCT GAG GAG GTG 720 
Gln Tyr Leu Ala His Ser Lys Gln Val Phe Arg Glu Ala Ala Cln Asn Pro Glu Glu Val 236 
CCC GAG GTC TTC CTC ACC GCT TTG CCC GCC CCC AAG CCC ACC CTG CGC TAC TTC ACC ACC 780 
Ala Glu Val Phe Leu Thr Ala Leu Arg Ala Pro Lys Pro Thr Leu Arg Tyr Phe Thr Thr 256 
GAG CGC TTC CTG CCC CTG CTG CCC ATG CCC CTG GAC CAC CCC AGC CCC TCC AAC TAC GTC 840 
Clu Arg Phe Leu Pro Leu Leu Arg Met At-g Leu Asp Asp Pro Ser Cly Ser Asn Tyr Val 276 
ACC GCC ATG CAC CGG GAA GTG TTC GGC GAC GTT CCG GCA AAG GCC GAG GCT GGG GCC GAG 900 
Thr Ala Met His Arg Glu Val Phe Gly Asp Val Pro Ala Lys Ala Glu Ala Gly Ala Glu 296 
GCT GGG CCC GGG CCC CCC CCT GGG GCA GAG GAC GAG CCC GGG CCC ACT CCC GTG GGG GAC 960 
Ala Gly Gly Gly Ala Gly Pro Gly Ala Glu Asp Glu Ala Gly Arg Ser Ala Val Gly Asp 316 
CCT GAG CTC CCC CAT CCT CCC CCC GCC CCG CAG TAA AGG CTT CCT CAG CCC CTG TCT CCC 1020 
Pro Glu Leu Gly Asp Pro Pro Ala Ala Pro Gin *it* 327 
CCC CCC TTC TTT GTC CCC TGG GTC TGT GTG GTC CCT CCC CAT CCC CCC CCC GTA GCA GCT 1080 
GTG GGT CGC TAA TTA AGA TAG ATC GCG TTA GCC AGT TTT ACC AGC GCA GCT AGG CGC CAT 1140 
GGC GTC CCC TGT AAT CCC AGC GCT TTC CGA GGC GGA GGC AGG AGG ATC GCT CAA CCC CCC 1200 
GAG TTG GAG ACC AGC CAG AGC AAC ACA GTG ACA CCC CCA TCT CTA CAA AAA TAA AGA AAA 1260 -___-- 
TTT AAA AAT cAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA 1320 
AAA AA 1325 
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deduced amino acid sequence, showing a 
hydrophobic pocket in this area (fig.3), supports 
the conclusion of Murdock et al. [19] that this se- 
quence contains the substrate binding site. This 
kind of structure is shared by several proteins in- 
teracting with steroid hormones [20]. 
The amino acid sequence deduced from cDNA is 
predicted to contain 327 amino acid residues with 
a calculated A4, of 34853. This value is in agree- 
ment with values obtained in SDS-PAGE using 
purified enzyme (see [lo]). Of the 327 amino acids, 
there are 6 cysteine residues, 40 acid residues, 32 
basic residues, and 20 aromatic residues (table 1). 
The amino acid composition calculated from the 
cDNA-deduced sequence agrees well with that ob- 
tained by direct chemical analysis of the purified 
protein [ 17,21,22]. 
The amino acid sequence of 17-HSD ‘we have 
deduced from cDNA does not contain potential 
Asn-X-Ser/Thr N-glycosylation sites [23], confir- 
ming the finding that 17-HSD is not a glycoprotein 
[ 10,241. One potential cyclic AMP-dependent 
phosphorylation site (base-base-X-Ser) [25] is 
presented in the 17-HSD sequence at position 
131-134 (fig.1). Varying degrees of possible 
phosphorylation of 17-HSD may explain the 
microheterogeneity found in isoelectric focusing of 
the purified enzyme [26]. 
Table 1 
The amino acid composition of the subunit of III-HSD 
Residues per Burns [17] Jarabak [211a Nicolas [221a 
polypeptide 
deduced 
from cDNA 
Ala 38 36 54 54 
Arg 23 22 37 34-36 
Asn 5 
Asp 17 21 40 54-56 
GYs 6 6 10 12 
Gln 8 
Glu 23 28 51 68-70 
Gly 32 31 50 48 
His 7 7 11 14 
Ile 4 4 7 20 
Leu 42 41 66 66 
Lys 9 10 20 30 
Met 6 4 5 12 
Phe 13 13 20 24 
Pro 20 19 31 40 
Ser 19 19 34 40 
Thr 16 16 29 32-34 
Trp 1 1 2 4 
Tyr 6 6 9 16 
Val 32 32 47 52 
N= 327 316 523 624 + 4 
a Residues per enzyme molecule assuming that 17-HSD is 
composed of two identical subunits 
100 200 300 
AMINO ACID RESIDUE NUMBER 
Fig.3. Hydropathicity profile of the deduced amino acid sequence of human placental 17-HSD, determined according to Hopp and 
Woods [27]. The area thought to be involved in substrate binding is indicated by a bar. Negative values indicate hydrophobic regions 
of the protein. 
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A computer homology search of the cDNA of 
I7-HSD and the amino acid sequence of the deriv- 
ed protein was performed against The Genetic Se- 
quence Data Bank (GenBank) and The National 
Biomedical Research Foundation (NBRF) Protein 
Data Bank. No significant homology with other 
proteins or DNA sequences was found. 
Our cloning of the cDNA of human placental 
17-HSD will be followed by studies on the gene 
structure, which should facilitate studies on the 
hormonal regulation of this enzyme in a number of 
hormone-responsive tissues, such as human en- 
dometrium and breast epithelium. In these tissues, 
17-HSD may have important physiological 
regulator functions, and it may also be important 
for our understanding of the behavior of cancer in 
these tissues. 
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